SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that the Wellcome Trust Sanger Institute has developed a catalog of structural genomic changes in almost 800 cancer cell lines using the company’s Genome-Wide Human SNP Array 6.0. Cancer cell lines are invaluable reagents in analyzing the molecular biology of the disease as well as important tools in developing new healing methods.
